ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer
07 May 2021
bởiElaine Soliven
Maintenance treatment with olaparib showed progression-free survival (PFS) benefit in patients with platinum-sensitive relapsed ovarian cancer (PSR OC), particularly those with somatic BRCA mutation (BRCAm), according to results of the ORZORA* trial presented at SGO 2021.